Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00002745
First received: November 1, 1999
Last updated: February 8, 2013
Last verified: January 2013
  Purpose

Phase II trial to study the effectiveness of aminocamptothecin in treating patients who have refractory or recurrent Hodgkin's disease or non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.


Condition Intervention Phase
Lymphoma
Drug: aminocamptothecin
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: PHASE II STUDY OF 9-AMINOCAMPTOTHECIN (9-AC/DMA, NSC# 603071) IN PREVIOUSLY TREATED HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA: IWF GRADES A-H

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Response [ Time Frame: 2 years post treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Toxicity [ Time Frame: day 1 of each cycle ] [ Designated as safety issue: Yes ]
  • 9-AC/DMA concentrations [ Time Frame: Pre-treatment cycle 1 and just prior to completion of cycle 1 ] [ Designated as safety issue: No ]

Enrollment: 37
Study Start Date: April 1996
Study Completion Date: January 2008
Primary Completion Date: April 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: aminocamptothecin
aminocamptothecin
Drug: aminocamptothecin
850 micrograms/square meter/day (total dose 2550 micrograms/square meter) via central venous catheter using infusion pump over 72 hours + one cycle Cycle repeated every 14 days for minimum of 6 cycles if partial or complete response

Detailed Description:

OBJECTIVES:

I. Evaluate the response rate and duration of response to aminocamptothecin (9-AC) in patients with refractory or relapsed Hodgkin's disease or non-Hodgkin's lymphoma.

II. Assess the toxicity of 9-AC in these patients. III. Validate a preliminary pharmacodynamic model relating total 9-AC concentration, albumin, and bilirubin to toxicity.

IV. Determine whether 9-AC concentrations correlate with response.

OUTLINE: Patients are stratified by disease histology (International Working Formulation (IWF) A-C vs IWF D-F) and center.

Patients receive aminocamptothecin IV continuously on days 1-3. Treatment repeats every 2 weeks for a minimum of 3 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease, partial response (PR), or complete response (CR) may receive 2 additional courses past best response (minimum of 6 courses if PR or CR). Patients are followed every 6 months for 2 years, and then annually thereafter.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically documented Hodgkin's disease (closed to accrual 4/15/2000) OR
  • Histologically documented non-Hodgkin's lymphoma (NHL) of one of the following International Working Formulation (IWF) histologies:

    • Small lymphocytic (absolute lymphocyte count less than 5,000)
    • IWF A Follicular, predominantly small cleaved cell
    • IWF B Follicular mixed
    • IWF C Follicular large cell
    • IWF D* Diffuse small cleaved cell
    • IWF E* Diffuse mixed
    • IWF F* Diffuse large cell
    • IWF G* Large cell, immunoblastic
    • IWF H* * Accrual of patients with these diagnoses closed 4/15/2000
  • Pathology review required within 60 days of registration
  • Refractory to or relapsed after prior chemotherapy as follows:

    • Low-grade NHL (IWF A-C): 1 or 2 prior therapies
    • Intermediate-grade NHL (IWF D-H): 1 prior therapy (stratum closed 4/15/2000)
    • Hodgkin's disease: 1 or 2 prior therapies (stratum closed 4/15/2000)
  • Treatment with the same drugs on 2 different schedules considered 1 therapy
  • Measurable disease by physical exam or imaging studies
  • Mass larger than 1 x 1 cm
  • Documented progression required of previously irradiated lesions
  • The following are not considered measurable:

    • Ascites or pleural effusion
    • Bone marrow involvement
    • Positive barium studies
    • Bony disease (lytic lesions noted)
    • No mantle cell or transformed lymphoma
    • No parenchymal or leptomeningeal CNS disease
  • A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS:

  • Age: 18 and over
  • Performance status: CALGB 0-2
  • Unless hypersplenism or biopsy-proven bone marrow involvement:

    • Absolute granulocyte count at least 1,500/mm3
    • Platelet count at least 100,000/mm3
  • Bilirubin normal
  • AST no greater than 4 times normal
  • Creatinine normal
  • No suspected HIV infection
  • No second malignancy within past 5 years except:

    • Curatively treated carcinoma of the cervix
    • Curatively treated basal cell skin cancer
    • No uncontrolled infection or other serious medical condition
    • No psychiatric condition that precludes informed consent
    • Not pregnant or nursing
    • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

  • No prior allogeneic or autologous bone marrow transplant
  • More than 3 weeks since chemotherapy (6 weeks since nitrosoureas, melphalan, or mitomycin)
  • No prior camptothecin
  • More than 3 weeks since radiotherapy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002745

Locations
United States, District of Columbia
Walter Reed Army Medical Center
Washington, District of Columbia, United States, 20307-5000
United States, Minnesota
University of Minnesota Cancer Center
Minneapolis, Minnesota, United States, 55455
United States, Missouri
Washington University Barnard Cancer Center
Saint Louis, Missouri, United States, 63110
United States, New Jersey
Cooper Cancer Institute
Camden, New Jersey, United States, 08103
St. Joseph's Hospital and Medical Center
Paterson, New Jersey, United States, 07503
Sponsors and Collaborators
Investigators
Study Chair: Nancy L. Bartlett, MD Washington University Siteman Cancer Center
  More Information

Additional Information:
Publications:
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00002745     History of Changes
Other Study ID Numbers: NCI-2012-02791, U10CA031946, CLB-9551, CDR0000064666
Study First Received: November 1, 1999
Last Updated: February 8, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by National Cancer Institute (NCI):
Waldenstrom macroglobulinemia
recurrent grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma
recurrent small lymphocytic lymphoma

Additional relevant MeSH terms:
Hodgkin Disease
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on April 17, 2014